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OBJECTIVES We compared the hemodynamic effects of dobutamine and enoximone administration before
and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with
chronic heart failure (HF).
BACKGROUND Patients with HF on beta-blocker therapy may need hemodynamic support with inotropic
agents, and the hemodynamic response may be influenced by both the inotropic agent and the
beta-blocker used.
METHODS The hemodynamic effects of dobutamine (5 to 20 g/kg/min intravenously) and enoximone
(0.5 to 2 mg/kg intravenously) were assessed by pulmonary artery catheterization in 29
patients with chronic HF before and after 9 to 12 months of treatment with metoprolol or
carvedilol at standard target maintenance oral doses. Hemodynamic studies were performed
after 12 h of wash-out from all cardiovascular medications, except the beta-blockers that
were administered 3 h before the second study.
RESULTS Compared with before beta-blocker therapy, metoprolol treatment decreased the magnitude
of mean pulmonary artery pressure (PAP) and pulmonary wedge pressure (PWP) decline
during dobutamine infusion and increased the cardiac index (CI) and stroke volume index
(SVI) response to enoximone administration, without any effect on other hemodynamic
parameters. Carvedilol treatment abolished the increase in heart rate, SVI, and CI and caused
a rise, rather than a decline, in PAP, PWP, systemic vascular resistance, and pulmonary
vascular resistance during dobutamine infusion. The hemodynamic response to enoximone,
however, was maintained or enhanced in the presence of carvedilol.
CONCLUSIONS In contrast with its effects on enoximone, carvedilol and, to a lesser extent, metoprolol
treatment may significantly inhibit the favorable hemodynamic response to dobutamine. No
such beta-blocker–related attenuation of hemodynamic effects occurs with enoximone. (J Am
Coll Cardiol 2002;40:1248–58) © 2002 by the American College of Cardiology Foundation
Despite the improvement obtained with the administration
of angiotensin-converting enzyme inhibitors (ACEIs) and
beta-blockers, the natural history of chronic heart failure
(HF) remains progressive, and many patients eventually
develop decompensation. During decompensation, patients
with HF are limited by dyspnea and fatigue at rest or with
minimal exertion, require frequent hospitalizations, have a
higher mortality rate, and both symptoms and prognosis
become critically dependent on hemodynamic conditions
(1–3). Treatment with inotropic agents may, thus, become
necessary (4,5). In addition, beta-blockers, which are indi-
cated for their long-term favorable actions (6–8), may be
less well-tolerated in advanced HF patients because of their
initial negative inotropic activity resulting from withdrawal
of adrenergic support (9,10). The concomitant administra-
tion of an inotropic agent and a beta-blocker, therefore, may
be necessary both in patients already on maintenance
beta-blocker treatment who have progressed to decompen-
sated HF and in patients with advanced HF who do not
tolerate the initiation of beta-blockade (11,12). However,
few studies have assessed the hemodynamic effects of
different types of inotropic agents in patients on beta-
blocker therapy (12–14).
The most common inotropic agents presenting clinical
practice are the beta-adrenergic receptor agonist dobut-
amine and the type III phosphodiesterase (PDE) inhibitors,
milrinone and enoximone. These two classes of drugs have
important differences (15,16). In human ventricular myo-
cardium, dobutamine is a partial beta1-receptor agonist (17)
but also has action on beta2- and alpha1-postsynaptic
adrenergic receptors. Its inotropic effects are, therefore,
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dependent on the degree of occupancy of the beta-
adrenergic receptors and on the activity of beta-adrenergic
signal transduction mechanisms (18,19). The type III PDE
inhibitors block the breakdown of cyclic adenosine mono-
phosphate, which in myocardial cells results in activation of
protein kinase A, phospholamban, and L-type calcium
channel phosphorylation. Phoshorylation of phospholam-
ban results in relief of this regulatory protein’s inhibition of
calcium adenosine triphosphatase activity, producing posi-
tive lusitropic and inotropic effects (15,16). As site of action
of the type III PDE inhibitors is distal to beta-adrenergic
receptors, their activity is less influenced by the degree of
expression and coupling of beta-adrenergic receptors
(12,14,19).
The beta-blockers metoprolol and carvedilol have both
been shown to favorably affect the prognosis of the patients
with HF (6–8). These agents have meaningful pharmaco-
logic differences that might influence the response to ino-
tropic agents (20–22). Metoprolol administration to pa-
tients with HF causes the upregulation of beta1-adrenergic
receptors and leaves unoccupied, or may even recouple,
beta2-adrenergic receptors (21,23). In contrast, carvedilol
blocks both beta1- and beta2-adrenergic receptors, and also
has alpha1-antagonist activity (21). We hypothesized that
these differences would influence the hemodynamic re-
sponses to inotropic agents that act on adrenergic receptors,
but would have less or no effect on agents that act beyond
them. The aim of our study was, thus, to compare the
hemodynamic effects of dobutamine and enoximone before
and after long-term beta-blocker therapy with metoprolol or
carvedilol in patients with chronic HF.
METHODS
Patients. We studied patients with chronic HF caused by
an ischemic or nonischemic cardiomyopathy who had New
York Heart Association (NYHA) functional class II to IV
symptoms, a left ventricular ejection fraction (LVEF)
35% by radionuclide ventriculography, and ongoing treat-
ment with furosemide and an ACEI. We excluded patients
with an acute ischemic event or a coronary revascularization
procedure within three months; a history of alcohol abuse,
primary valve disease or congenital heart disease; frequent
ventricular premature beats and/or runs of ventricular tachy-
cardia; contraindications to beta-blocker therapy (e.g., bron-
chial asthma sensitive to the administration of beta-
agonists); concomitant treatment with other beta-blockers,
alpha-antagonists, calcium antagonists, or antiarrhythmic
agents (except amiodarone). The protocol was approved by
the Ethics Committee of the Hospital of Brescia. Written
informed consent was obtained from all study patients.
Protocol. Hemodynamic measurements were obtained us-
ing a balloon-tipped, flow-directed pulmonary artery cath-
eter inserted percutaneously into the right internal jugular
vein. Cardiac output was assessed by the thermodilution
method with the mean of three consecutive measurements
with 15% variations between each other used for data
analysis. Derived hemodynamic variables were calculated
using standard formulas.
Once a reproducible baseline was obtained, the hemody-
namic response to the inotropic agents was assessed. Be-
cause of its shorter elimination half-life, dobutamine was
infused first, followed by a re-equilibration period of at least
1 h, then by enoximone administration. Dobutamine was
infused at the increasing doses of 5, 10, 15, and 20
g/kg/min with hemodynamic values measured after 15
min of infusion at each dose level. Dobutamine infusion was
then discontinued, and hemodynamic variables were al-
lowed to return to within 10% of the initial baseline values
during the re-equilibration period. The second baseline,
pre-enoximone measurements were obtained in triplicate,
and enoximone was then administered as intravenous bolus
injections in increasing increments of 0.5 mg/kg, repeated
every 20 min to a maximal final dose of 2.0 mg/kg.
After the initial hemodynamic study, each patient was
randomized to metoprolol tartrate or carvedilol, added to
the ongoing therapy for HF, according to a protocol
described previously (22). A second hemodynamic study
that included the assessment of the response to dobutamine
and enoximone administration was performed after 9 to 12
months of beta-blocker therapy, using the same protocol of
the first study. In order to detect the maximal effects of the
beta-blocker treatment on the hemodynamic response to the
inotropic agents, the second hemodynamic study was per-
formed 3 h after the last administration of either metoprolol
or carvedilol at the standard doses used during chronic
maintenance therapy. In contrast, all other cardiovascular
medications were withdrawn at least 12 h before both the
hemodynamic studies.
In addition to pulmonary artery catheterization, all pa-
tients were assessed by the NYHA functional classification
and by radionuclide ventriculography, for the assessment of
LVEF and volumes, before and after 9 to 12 months of
beta-blocker therapy at maintenance doses.
Statistical analysis. Each of the 29 subjects was treated
chronically with a beta-blocker (carvedilol or metoprolol)
and acutely with two inotropes (dobutamine and enoxi-
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
ANOVA  analysis of variance
CI  cardiac index
HF  heart failure
HR  heart rate
LVEF  left ventricular ejection fraction
MAP  mean arterial pressure
NYHA  New York Heart Association
PAP  mean pulmonary artery pressure
PDE  phosphodiesterase
PVR  pulmonary vascular resistance
PWP  pulmonary wedge pressure
SVI  stroke volume index
SVR  systemic vascular resistance
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mone) before and after beta-blocker treatment. There were
no missing values. Using mean and variance data for the
patients included in a previous study (14) and assuming a
within-subject correlation of 0.50 and two-sided alpha of
0.05, a sample size of 13 carvedilol-treated subjects was
calculated to have 90% power to detect a difference from
baseline to end of study of 0.05 l/min/m2 per g/kg/min in
slope (over dobutamine dose of 0 to 20 g/kg/min) of
cardiac index (CI). This difference corresponds to a 45%
relative decrease in slope, comparable to the 53% decrease
seen in the previous study (14). Comparison of baseline data
between the beta-blocker groups was by unpaired t test and
chi-square test, as appropriate. Effects of chronic treatment
were assessed by paired t test within-group and by analysis
of variance (ANOVA) to compare between-group changes.
Effects of acute treatment were assessed as changes from
before dobutamine or enoximone administration, separately
by each beta-blocker and inotrope. The paired t test was
used to assess the within-visit effect of dose. Taking the
design as that of the split-split-plot experiment (24,25),
three-way repeated measures ANOVA was used to assess
differences in linear slope of the dose-response curves. The
paired t test was used to assess the within-dose effect of visit,
when the slope differences were significant. A two-tailed p
value 0.05 was considered significant. Results are ex-
pressed as mean  SD unless otherwise specified. Reported
p values are not adjusted for multiple comparisons.
RESULTS
Patient characteristics and response to beta-blocker
treatment. We studied 34 patients, 27 males and 7 females,
age 58  10 years, with chronic HF caused by idiopathic
dilated cardiomyopathy (22 patients) or by previous myo-
cardial infarction (12 patients). Eight patients were NYHA
functional class II, 25 were class III, and 1 was class IV. The
patients had severe left ventricular dysfunction with a mean
LVEF of 18.3  6.6% and a moderate-severe impairment
of maximal functional capacity, with a mean peak oxygen
consumption of 13.3  3.5 ml/kg/min. At end of study, all
patients were treated with furosemide and an ACEI, 27
were on digoxin, 21 on spironolactone, and 2 patients were
receiving amiodarone.
Patients randomized to metoprolol and to carvedilol were
similar with respect to all pretreatment characteristics (Ta-
ble 1). Five patients died before the end of the study, three
suddenly (two in the metoprolol and one in the carvedilol
group) and two for worsening HF. The remaining 29
patients completed the protocol and were reassessed after
10.4  1.2 months (median time, 10 months) of beta-
blocker therapy. Long-term therapy with metoprolol (mean
dose, 129  38 mg daily) or carvedilol (mean dose, 43  11
mg daily) was associated with a significant improvement in
clinical symptoms, left ventricular function, and hemody-
namic parameters, with no significant difference in these
parameters between the two study groups (Table 2).
Hemodynamic response to the inotropic agents. No
significant difference in any parameter was detected before
dobutamine compared to before enoximone infusion. The
changes from baseline in the main hemodynamic parame-
ters caused by dobutamine and enoximone administration,
before and after metoprolol or carvedilol treatment, respec-
tively, are shown in Figures 1 to 5. Before beta-blocker
administration, CI increased after both dobutamine and
enoximone infusions, in both treatment groups. Metoprolol
treatment did not change the response to dobutamine,
whereas the response to enoximone was augmented. Carve-
dilol treatment was associated with a significant inhibition
of the CI response to dobutamine but not to enoximone
administration (Fig. 1). Similarly, metoprolol treatment had
no effect on the heart rate (HR) and stroke volume index
(SVI) responses to dobutamine and slightly increased them
after enoximone; carvedilol significantly inhibited these
responses to dobutamine but not to enoximone (Fig. 2).
Before beta-blocker therapy, dobutamine or enoximone
administration caused a decline in both the pulmonary
wedge pressure (PWP) and mean right atrial pressure.
Metoprolol treatment was associated with a reduction in the
magnitude of the PWP decline without any change in the
direction of this response. Carvedilol treatment had a
greater effect than metoprolol on the PWP lowering re-
sponse of dobutamine as, in its presence, dobutamine
infusion was associated with an increase, rather than a
decline, in PWP. In contrast, the response to enoximone
administration was not influenced by either metoprolol or
carvedilol treatment (Fig. 3).
Before either metoprolol or carvedilol treatment, the
mean arterial pressure (MAP) was not significantly changed
by dobutamine infusion (Fig. 4). After metoprolol treat-
ment MAP slightly, but significantly, increased from pre-
Table 1. Baseline Characteristics of the Patients According to
Treatment Group
Metoprolol
(n  17)
Carvedilol
(n  17)
Age, yrs 60  8 56  11
Gender (males/females), n 3/14 4/13
Cause (IDC/CAD), n 11/6 11/6
Atrial fibrillation, n 3 4
NYHA functional class, II/III/IV 5/12/0 3/13/1
LVEF, % 19.5  7.5 17.0  5.6
Peak VO2, ml/kg/min 13.7  4.0 13.0  3.1
CI, l/min/m2 2.62  0.64 2.24  0.50
PWP, mm Hg 23  11 29  11
Concomitant therapy
Furosemide, n, mg/day 17, 63  33 17, 74  72
Captopril, n, mg/day 3, 125  43 6, 80  61
Enalapril, n, mg/day 14, 15  5 11, 20  8
Digoxin, n, mg/day 15, 0.17  0.13 12, 0.16  0.06
Amiodarone, n, mg/day 1, 200 1, 200
There was no significant difference between the two groups with respect to all the
pretreatment characteristics.
CAD  coronary artery disease; CI  cardiac index; IDC  idiopathic dilated
cardiomyopathy; LVEF  left ventricular ejection fraction; NYHA  New York
Heart Association; PWP pulmonary wedge pressure; VO2 oxygen consumption.
1250 Metra et al. JACC Vol. 40, No. 7, 2002
Inotropic Agents and Beta-Blockers in HF October 2, 2002:1248–58
infusion values during dobutamine infusions of 15 and 20
g/kg/min, respectively. This MAP increase was likely
related to the increase in the CI, as it was accompanied by
a dose-dependent decline in systemic vascular resistance
(SVR). In contrast, enoximone caused a dose-dependent
decline in MAP and SVR, both before and after metoprolol
therapy. The MAP and SVR response to dobutamine was
significantly affected by carvedilol treatment. In the presence
of carvedilol, dobutamine infusion caused a dose-dependent
increase in the MAP, which was accompanied by a similar
increase in the SVR, in contrast with the decline observed
before carvedilol treatment. In contrast, the MAP and SVR
decline during enoximone administration was augmented by
carvedilol therapy (Fig. 4).
Compared with effects on MAP and SVR, similar re-
sponses were observed with respect to mean pulmonary
artery pressure (PAP) and pulmonary vascular resistance
(PVR) (Fig. 5). Before treatment with beta-blocking agents,
these parameters declined during the administration of both
inotropic agents. After metoprolol therapy dobutamine
produced a directionally similar, but somewhat blunted,
PAP and PVR response, while the enoximone PAP and
PVR responses were unchanged. In contrast, after carvedilol
treatment dobutamine infusion caused a significant, dose-
dependent increase in the PAP and PVR, while the re-
sponse to enoximone was similar to the pre-carvedilol
treatment effects (Fig. 5).
DISCUSSION
Potential need of concomitant beta-blocker and inotro-
pic therapy. Because of its beneficial effects on prognosis,
beta-blocker therapy is now indicated in all the patients
with chronic HF who do not have major contraindications.
As a result, the number of patients on beta-blocker therapy
who develop decompensated HF and who need inotropic
therapy is likely to increase. Second, although the beneficial
effects of beta-blockade have been shown in selected groups
of patients with advanced HF (8), beta-blockers may be
poorly tolerated, and the initiation of therapy may be
particularly difficult in these patients (9,21). Thus, the
concomitant administration of the inotropic agents and
beta-blockers may become necessary both in the patients
who develop decompensated HF while on chronic beta-
blocker therapy and in patients who cannot tolerate the
initiation of beta-blockers. However, meaningful differences
are present among beta-blockers used to treat HF, as well as
in inotropic agents. Thus, it is important to know whether
these differences account for significant degrees of interac-
tion between individual inotropes and beta-blockers when
these two classes of compounds are used in combination.
With this aim, we assessed the response to the two inotropic
agents dobutamine and enoximone in a group of patients
with HF, before and after long-term treatment with meto-
prolol or carvedilol. We excluded patients with advanced
HF and in unstable clinical conditions in whom the initia-
tion of beta-blocker treatment might be difficult and the
hemodynamic responses may be affected by the instability of
the clinical and hemodynamic conditions. However, we
maintain that our results may be extrapolated to patients
with advanced HF, whose response to beta-adrenergic
agonists may be compromised to an even a greater extent
because of even greater impairment of beta-adrenergic
signal transduction mechanisms (14,18,19).
Dobutamine-metoprolol interaction. Our study demon-
strates that the hemodynamic response to different inotropic
agents may be profoundly influenced by the type of ongoing
beta-blocker therapy. In particular, the hemodynamic re-
sponse to the beta-adrenergic agonist dobutamine was
affected only slightly by metoprolol, but to a far greater
extent by carvedilol therapy. Before beta-blocker therapy,
dobutamine infusion was associated with the expected
hemodynamic effects, consisting of a dose-dependent in-
Table 2. Hemodynamic Responses at Rest
Metoprolol (n  14) Carvedilol (n  15)
p (ANOVA)Baseline EOS Baseline EOS
LVEF (%) 20.4  7.7 30.0  14.0‡ 17.0  5.9 27.9  11.1‡ NS
Left ventricular end-diastolic volume (ml/m2) 174  57 168  100 174  72 145  56* NS
NYHA functional class, I/II/III/IV 0/5/9/0 3/10/1/0‡ 0/3/11/1 4/7/3/1‡ NS
Peak VO2 (ml/kg/min) 13.8  4.3 15.7  4.1‡ 13.2  3.0 13.8  3.7 NS
Heart rate (beats/min) 87  14 66  8‡ 92  17 69  16‡ NS
Mean arterial pressure (mm Hg) 84  9 85  11 92  14 90  9 NS
CI (l/min/m2) 2.78  0.78 2.74  0.81 2.37  0.53 2.66  0.83 NS
SVI (ml/beat/m2) 33  11 42  13‡ 27  8 41  14‡ NS
Left ventricular stroke work index (gm/m2) 29  13 40  18† 24  9 40  15‡ NS
Systemic vascular resistance (dynscm5) 1,315  501 1,358  375 1,593  537 1,493  575 NS
Mean right atrial pressure (mm Hg) 8  3 6  2* 11  5 8  5* NS
PAP (mm Hg) 27  10 23  11 34  11 27  10‡ NS
PWP (mm Hg) 22  9 18  9 27  8 20  9‡ NS
PVR (dynscm5) 107  96 92  51 136  80 124  61 NS
*p  0.05; †p  0.01; ‡p  0.001 for differences between pre- and post-treatment values (within each group). The p (analysis of variance [ANOVA]) denotes significance
of differences in the magnitude of change from baseline to end of study between the metoprolol group and the carvedilol group. Values reflect data in patients with paired
measurements.
EOS  end of study; SVI  stroke volume index; PAP  mean pulmonary artery pressure; PVR  pulmonary vascular resistance. Other abbreviations as in Table 1.
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crease in CI, HR, and SVI and a decrease in ventricular
filling pressures (15,16,18). The SVR and PVR also showed
a dose-dependent decline, mainly related to the increase in
the CI as the alpha1-agonist vasoconstrictive activity of
dobutamine is counteracted by its peripheral beta2-
receptor–mediated vasodilating action (16).
Consistent with previous data (14), metoprolol only
slightly affected the hemodynamic response to dobutamine
infusion. This may be explained by many mechanisms. First,
long-term metoprolol therapy may increase the beta1-
adrenergic receptors density and improve beta-adrenergic
signal transduction mechanisms, for instance, through the
inhibition of the beta-adrenergic receptor kinase or down-
regulation in Gi (12,13,18,20). These adjustments may
sensitize the heart to beta1-adrenergic stimulation so that,
when metoprolol is removed from the beta-receptors by
mass action, the dobutamine response is preserved or even
accentuated. Second, dobutamine has reasonably high affinity
for myocardial beta2-adrenergic receptors (15,16), which have
significant inotropic and chronotropic effects and are left
unoccupied by the selective beta1-antagonist metoprolol. In
addition, during the chronic administration of beta1-selective
agents such as metoprolol, myocardial beta2-receptors exhibit
improved coupling to intracellular signal transduction mecha-
nisms, through cross-regulation (23). On the other hand, the
slight reduction in the response of the PWP and PAP to
dobutamine infusion that was observed after metoprolol ther-
apy was likely related to beta1-receptor occupancy by metopro-
lol, and is consistent with a slight inhibition of the inotropic
response to the beta1-agonist effects of dobutamine.
Figure 1. Absolute changes (mean  SEM) from baseline in cardiac index after dobutamine (left figures) or enoximone (right figures) administration,
before (open symbols) and after (closed symbols) long-term beta-blocker treatment with metoprolol (upper figures) or carvedilol (lower figures).
Asterisks immediately above or below the standard error bars indicate significance of dose-specific differences from baseline. Asterisks between the
dose-response curves indicate significance of dose-specific differences in the changes from baseline between before and after beta-blocker therapy.
Significance values at the bottom of each graph indicate differences between the slopes of the dose response curves before and after metoprolol or carvedilol
treatment. *p  0.05; **p  0.01; ***p  0.001.
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Figure 2. Absolute changes (mean  SEM) from baseline in heart rate and stroke volume index after dobutamine or enoximone administration, before (open symbols) and after (closed symbols) long-term
beta-blocker treatment with metoprolol (upper figures) or carvedilol (lower figures). Significance of symbols as in Figure 1.
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Figure 3. Absolute changes (mean  SEM) from baseline in the pulmonary wedge pressure and right atrial pressure after dobutamine or enoximone administration before (open symbols) and after (closed
symbols) long-term beta-blocker treatment with metoprolol (upper figures) or carvedilol (lower figures). Significance of symbols as in Figure 1.
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Figure 4. Absolute changes (mean  SEM) from baseline in the mean arterial pressure and systemic vascular resistance after dobutamine or enoximone administration before (open symbols) and after (closed
symbols) long-term beta-blocker treatment with metoprolol (upper figures) or carvedilol (lower figures). Significance of symbols as in Figure 1.
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Figure 5. Absolute changes (mean  SEM) from baseline in the mean pulmonary artery pressure and pulmonary vascular resistance after dobutamine or enoximone administration before (open symbols) and
after (closed symbols) long-term beta-blocker treatment with metoprolol (upper figures) or carvedilol (lower figures). Significance of symbols as in Figure 1.
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Dobutamine-carvedilol interaction. Unlike metoprolol,
carvedilol profoundly affected the hemodynamic responses
to dobutamine. The increases in the CI, HR, and SVI
produced by the baseline dobutamine infusion were almost
completely inhibited after carvedilol administration. This
striking difference between the effects of the two beta-
blockers may be ascribed to their different mechanisms of
action. Unlike metoprolol, carvedilol does not cause opera-
tional beta1-adrenergic receptor upregulation and also
blocks beta2-adrenergic receptors (21). These properties,
although potentially useful in the long-term (22), may cause
a greater inhibition of the effects of dobutamine. In addition
to its more comprehensive antiadrenergic action, carvedilol
also exhibits “tight binding” to beta-adrenergic receptors,
making it more difficult for an agonist to displace it (26).
Concomitant carvedilol therapy also affected the dobut-
amine vascular resistance responses. In contrast with the
decreases in SVR and PVR observed in patients treated with
metoprolol, dobutamine infusion was associated with a
dose-dependent increase in SVR and PVR in carvedilol-
treated subjects. This effect has also been described in
previous studies (12,14), and may be explained by persistent
blockade of vascular beta2-adrenergic receptors, but not
alpha1-adrenergic receptors, by carvedilol. In fact, carvedilol
has a greater dissociation constant for alpha1- compared
with beta1-adrenergic receptors (21). In addition, the
alpha1-antagonist activity of carvedilol tends to decrease
during long-term treatment, similarly to that shown with
pure alpha1-adrenergic antagonists in the patients with HF
(27). The persistent blockade of the beta1- and the beta2-
adrenergic receptors with a concomitant stimulation of the
peripheral alpha1-adrenergic receptors, thus, may explain
the increase in the peripheral vascular resistance and PVR
caused by dobutamine after long-term carvedilol adminis-
tration.
Enoximone-beta-blocker interactions. In contrast with
dobutamine, the hemodynamic responses to enoximone
were less affected and, in the case of some parameters, even
enhanced after long-term beta-blockade with either meto-
prolol or carvedilol. These data are in accordance with
previous studies showing the favorable hemodynamic effects
of milrinone administration during concomitant carvedilol
treatment (12,14). The maintenance of the effects of the
PDE inhibitors during carvedilol therapy is consistent with
their mechanism of action, which is distal to and indepen-
dent of occupancy of the beta-adrenergic receptors
(15,16,19). These results also support the potential utility of
combined therapy with a beta-blocker and a PDE inhibitor
when it is necessary to improve hemodynamics while
maintaining the long-term beneficial effects of beta-
blockade in patients with advanced HF (28–30).
Conclusions. In conclusion, our study shows that the
hemodynamic response to dobutamine may be influenced by
the type of concomitant beta-blocker therapy. Prior and
ongoing metoprolol therapy was only associated with an
attenuation of the decrease in PWP and PAP produced by
dobutamine infusion. In contrast with carvedilol treatment,
the administration of dobutamine was associated with an
almost complete inhibition of the increases in CI, HR, and
SVI, and a tendency to a increase, rather than decrease, in
MAP, SVR, PWP, PAP, and PVR. In marked contrast
with dobutamine, the hemodynamic response to enoximone
was not significantly inhibited by either concomitantly
administered beta-blocking agent, and some responses were
enhanced. These data favor the use of a PDE inhibitor over
dobutamine when it is necessary to administer an inotropic
agent to a patient on beta-blockade, particularly carvedilol.
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